Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

22.58 -0.47 (-2.04%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 18, 2023

Via Benzinga

Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 18, 2023

Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.

Via Benzinga

Where Apellis Pharmaceuticals Stands With Analysts ↗

July 18, 2023

Via Benzinga

The Latest Analyst Ratings for Apellis Pharmaceuticals ↗

June 13, 2023

Via Benzinga

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is a Stock Spotlight on 5/25

May 25, 2023

Via Investor Brand Network

Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know ↗

May 05, 2023

Via Benzinga

Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views ↗

May 05, 2023

The company easily beat sales calls on the back of Syfovre, a geography atrophy drug.

Via Investor's Business Daily

Why Are Apellis Pharmaceuticals Shares More Down 20% Today? ↗

July 17, 2023

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 17, 2023

Via Benzinga

Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 17, 2023

Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...

Via Benzinga

The Latest Analyst Ratings for Apellis Pharmaceuticals ↗

May 05, 2023

Via Benzinga

Apellis Pharmaceuticals: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Ford Motor, AT&T, Frontier Communications And Other Big Stocks Moving Lower On Monday ↗

July 17, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Monday. Here are some big stocks recording losses in today’s session. Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares...

Via Benzinga

Apellis Pharma Crashes After Safety Report Undercuts Its Newest Eye Drug ↗

July 17, 2023

Now, investors are questioning the future for Apellis' Syfovre, an eye-disease treatment.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 17, 2023

Via Benzinga

Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket ↗

July 17, 2023

Gainers

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

July 17, 2023

It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!

Via InvestorPlace

Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

July 10, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 06, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 07, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study ↗

May 25, 2023

Via Benzinga

Why Shares of Annexon Are Plummeting Thursday ↗

May 25, 2023

Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.

Via The Motley Fool

Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

May 25, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Why These 3 Nasdaq Stocks Buckled Today ↗

May 16, 2023

The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.

Via The Motley Fool

Are Small Caps a Harbinger of Market Declines?

May 09, 2023

The iShares Russell 2000 ETF outperformed the S&P 500 last week, but that may be short-lived. Small-cap momentum is often a bellwether for broad-market action.

Via MarketBeat

Topics ETFs Stocks

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations ↗

May 05, 2023

Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and

Via Benzinga

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

May 04, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.